A groundbreaking drug, lenacapavir, has shown remarkable results in preventing HIV infections. In a clinical trial, 100% of the 5,000 women and adolescent girls in Uganda and South Africa who received twice-yearly injections of lenacapavir remained HIV-free. Another trial involving 3,265 men and gender-diverse individuals saw a 96% reduction in HIV incidence with the same regimen. Lenacapavir, already approved for treating some HIV cases, is now being tested for annual injections. A phase I trial with 40 healthy volunteers in the US showed that the drug remained in their blood plasma at protective levels a year after injection. The drug’s unique properties allow it to be administered daily or yearly, with larger doses forming a depot for gradual release. Gilead Sciences is planning a phase III trial to test annual shots in at-risk populations. The twice-yearly formulation is under review for FDA approval, expected by June.
Mitesh Patel
@forginglory
·
Mar 10 This is a wonder drug that just got too popular and now it’s only left for those with Doctors willing to get it approved and the well off willing to get it paid for. Look into how $hims helped get the cost down
Andy Schmidt
@andyaschmidt
·
3m It would be cruel to be in the control group of this one with the survival rates so low, and the potential efficacy looking like 50% in the eligible subgroup. I guess it is the same as not getting into the study at all, but it would be hard.
Janeharmony
@Janeharmony63
·
Mar 11 this drug won a Nobel prize, not “they” are trying to bury it as its off patent and does not make big pharma any money. ” they “don’t want cancer cured it’s a cash cow!
Aaron Pogue
@AaronPogue
·
1h I hold out hope that the will to solve the problem and the money that was available are both still there. They’ve just been removed from Congressional interference.
The next 6 months will be rough, but the scientists who were really dedicated to this research will stick it out.
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional
Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes.The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
